Merck KgaA has suffered a triple whammy in the last couple of days: First, Citibank and WestLB downgraded the company's stock. Then came news of a study showing that its MS drug Rebif performs no better than Teva Pharmaceuticals' Copaxone.
Meanwhile, some Israeli scientists have ID'd the genes that predict a positive response to Copaxone, opening the way for personalized treatment using the drug. Does that make it a quadruple whammy?
Bayer outbids Merck KGaA for Schering. Report
Merck KGaA buying control of Serono. Report
Teva launches pivotal MS drug study. Report
Read more on: Merck KGaA | Teva